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Background: Long-term persistence of immune response and safety of two doses of an A/California/07/2009 H1N1
pandemic influenza vaccine adjuvanted with AS03 (an a-tocopherol oil-in-water emulsion-based Adjuvant System)
administered 21 d apart was evaluated in Japanese adults [NCT00989612].
Methods: One-hundred healthy subjects aged 20–64 y (stratified [1:1] into two age strata 20–40 y and 41–64 y) received
21 d apart, two doses of AS03-adjuvanted 3.75 mg haemagglutinin (HA) H1N1 2009 vaccine. Immunogenicity data by
haemagglutination inhibition (HI) assay six months after the first vaccine dose (Day 182) and microneutralization assay
following each of the two vaccine doses (Days 21 and 42) and at Day 182 are reported here.
Results: Persistence of strong HI immune response was observed at Day 182 that met the US and European regulatory
thresholds for pandemic influenza vaccines (seroprotection rate: 95%; seroconversion rate: 93%; geometric mean fold-
rise: 20). The neutralizing antibody response against the A/Netherlands/602/2009 strain (antigenically similar to vaccine-
strain) persisted for at least up to Day 182 (vaccine response rate: 76%; geometric mean titer: 114.4) and paralleled the HI
immune response at all time points. No marked difference was observed in HI antibody persistence and neutralising
antibody response between the two age strata. The vaccine had a clinically-acceptable safety profile.
Conclusion: Two priming doses of H1N1 2009 pandemic influenza vaccine induced an immune response persisting for
at least six months after the first vaccine dose. This could be beneficial in evaluating the importance and effect of
vaccination with this AS03-adjuvanted pandemic influenza vaccine.
The H1N1 2009 epidemic in Japan started off as isolated outbreaks
in small clusters between May and July 2009. The number of cases
rose steadily from mid-August 2009 and peaked in November
2009.
1 An estimated 20 million cases (as of February 5, 2010)
2 and
202 deaths related to H1N1 2009 (as of the end of H1N1 2009
pandemic)
3 were recorded in Japan. The majority of infections were
recorded in school children and young adults, with the hospitaliza-
tion rates being highest in children aged 5–9y .
4,5 Although, adults
appeared to be less susceptible to the H1N1 clinical disease, H1N1
2009 related fatality peaked in adults aged 40–49 y in addition to
children aged , 10 y (as of August 10, 2010).
3,5
Clinical effectiveness of neuraminidase inhibitors, zanamivir
and oseltamivir has been reported.
6-8 These drugs are able to
mitigate morbidity and mortality caused by an influenza
pandemic. However, mass immunization is an effective interven-
tion against pandemic influenza. Identifying the necessity to make
available a large number of vaccine doses worldwide and the
potential for cross-reactive immunity, the World Health
Organization (WHO) supported the development of adjuvanted
pandemic influenza vaccines in parallel with non-adjuvanted
vaccines.
9,10 A H1N1 2009 pandemic vaccine utilizing 3.75 mgA /
California/07/2009 (H1N1)v-like haemagglutinin (HA) antigen
*Correspondance to: Hideyuki Ikematsu; Email: hikematsu@camiku.kyushu-u.ac.jp, ikematsu@gray.plala.or.jp
Submitted: 08/09/11; Revised: 10/14/11; Accepted: 10/19/11
http://dx.doi.org/10.4161/hv.18469
Human Vaccines & Immunotherapeutics 8:2, 260–266; February 2012; G 2012 Landes Bioscience
260 Human Vaccines & Immunotherapeutics Volume 8 Issue 2© 2012 Landes Bioscience.
Do not distribute.
adjuvanted with AS03 Adjuvant System (an a-tocopherol oil-in-
water emulsion-based Adjuvant System) was developed based on
GlaxoSmithKline Biologicals’ previous experience with the AS03-
adjuvanted prepandemic H5N1 vaccine.
11-13 This H1N1 2009
vaccine has demonstrated strong immunogenicity (fulfilling the
US and European regulatory guidance criteria for pandemic
influenza vaccines) and a clinically acceptable safety profile in
different populations.
14,15
In an open-label, single group study (NCT00989612) in
Japanese adults aged 20–64 y, two doses of this H1N1 2009
pandemic influenza vaccine administered 21 d apart was found
to be well-tolerated and highly immunogenic (all subjects
seroconverted/ were seroprotected 21 d after the second vaccine
dose), achieving the US and European regulatory guidance criteria
for pandemic influenza vaccines in adults.
16 This manuscript
presents follow-up data from the same population (stratified into
20–40 y and 41–64 y) on the persistence of humoral immune
response in terms of HI antibody titers against the vaccine-
homologous strain six months after primary vaccination with two
doses of this AS03-adjuvanted H1N1 2009 vaccine (at Day 182),
as well as neutralising antibody titers against the vaccine-
homologous strain following each of the two doses and six
months later (Days 21 and 42; Day 182). Data on the safety
profile of the vaccine up to Day 182 is also presented here.
Results
Study population. The six month follow-up phase of this study
was completed on April 19, 2010 (up to Day 182).
All 100 subjects who were part of the primary assessment and
had received two doses of the H1N1 2009 vaccine completed the
study up to Day 182 and were included in the according to
protocol (ATP) cohort for persistence. The median age of subjects
at the time of enrolment was 40.5 y (range: 21 to 59 y); 64% of
subjects were female and all were of Japanese heritage.
Immunogenicity. HI antibody immune response. The haemag-
glutination inhibition (HI) immune response against the H1N1
2009 strain after six months after the first vaccine dose (Day 182)
is presented in Table 1. The seroprotection rate (SPR) was 95%,
seroconversion rate (SCR) was 93%, with a corresponding
geometric mean titer (GMT) of 175.1 and geometric mean fold
rise (GMFR) of 20. These values still met and exceeded the
Center for Biologics Evaluation and Research (CBER) and
Committee for Medicinal Products for Human Use (CHMP)
guidance criteria for pandemic influenza vaccines. There was no
appreciable difference in HI antibody persistence between the two
age strata (overlapping 95% confidence intervals [CIs]). It is to be
noted that the samples from Day 0, Day 21 and Day 42 were
tested at the same time, while the Day 182 samples were tested
later without an assessment of variability from earlier time points.
Due to potential assay variability, a comparative interpretation of
the HI response at Day 182 with earlier time points should be
done with caution.
Neutralizing antibody response. Prior to receiving vaccination,
51% of subjects were seropositive for neutralising antibodies
against the A/Netherlands/602/09 strain and the corresponding
geometric mean titers (GMT) was low (8.5). Twenty-one days
after the first vaccine dose (Day 21), the GMT rose to 136.9, with
a vaccine response rate (VRR) of 74%. Following the second
vaccine dose, these values increased to 305.8 and 96%,
respectively. Six months after the first vaccine dose, persistence
of neutralizing antibody response against the A/Netherlands/602/
09 strain was evident (overall, GMT of 114.4 and VRR of 76%).
No difference in neutralizing immune response was observed
between the two age strata at any of the time points (overlapping
95% CIs) (Table 2). The proportion of subjects with antibody
titers equal or above different threshold of positivity have been
presented. The reverse cumulative curves for neutralizing
antibodies 21 d after each of the two vaccine doses and at Day
182 (Fig.1) and the neutralizing antibody titers for all time points
(Table 3) showed a large proportion of subjects with titers equal
or above the thresholds of 1:8, 1:16, 1:32 and 1:64, for six
months after the first vaccine dose.
Safety and reactogenicity. Overall, at least one unsolicited
symptom was reported in 46 subjects (20–40 y: 21 subjects; 41–
64 y: 25 subjects) during the 84 d post-vaccination follow-up
period, of which 18 were considered to be vaccine-related.
Diarrhea, nasopharyngitis and headache (five subjects each)
were the most frequently reported unsolicited symptoms.
Of these, four cases of diarrhea and one case of headache
were considered to be causally related to vaccination. One
subject reported an unsolicited symptom of Grade 3 intensity
(urticaria) which required medical attention and was unrelated to
vaccination.
Table1. Immune response in terms of haemagglutination inhibition antibodies against the vaccine homologous A/California/07/2009 strain at Day 182
(ATP cohort for persistence)
Age strata Time point Seroprotection rates Seroconversion rates Geometric mean titers Geometric mean fold rise
N % (95% CI) N % (95% CI) N Value (95% CI) N Value (95% CI)
Overall Pre-vaccination 100 6 (1.9–13.6) –– 100 8.8 (7.3–10.5) ––
Day 182 100 95 (88.7298.4) 100 93.0 (86.1297.1) 100 175.1 (144.22212.7) 100 20.0 (16.8223.8)
20240 Pre-vaccination 50 6 (1.3–16.5) –– 50 8.9 (7.1–11.1) ––
years Day 182 50 98.0 (89.4299.9) 50 96.0 (86.3299.5) 50 182.6 (141.12236.4) 50 20.6 (16.0226.5)
41264 Pre-vaccination 50 6 (1.3–16.5) –– 50 8.6 (6.8–10.9) ––
years Day 182 50 92.0 (80.8297.8) 50 90.0 (78.2296.7) 50 167.9 (124.52226.5) 50 19.4 (15.1225.1)
N, number of subjects with available results; CI, confidence interval; ATP, according to protocol.
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No potential immune mediated diseases (pIMD) or adverse
events of special interest (AESIs) were recorded during the
study period. Three serious adverse events (SAEs) were reported
in two subjects during the entire study period. One male
subject aged 44 y presented with ureteric calculi, approximately
four months after the second vaccine dose which was resolved
within three days and a female subject aged 36 y had a viral
infection and pharyngeal ulceration approximately four and
half months after the second vaccine dose which resolved
in seven and 11 d, respectively; none of the SAEs were considered
by the investigators to be vaccine-related. No fatalities were
reported.
Table2. Immune response in terms of neutralising antibodies against the A/Netherlands/602/09 strain [antigenically homologous to the vaccine strain]
(ATP cohort for immunogenicity)
Age strata Time point Vaccine response rates Geometric mean titers
N % (95% CI) N Value (95% CI)
Overall Pre-vaccination 100 – 100 8.5 (7.1–10.2)
Day 21 100 74.0 (64.3–82.3) 100 136.9 (97.0–193.3)
Day 42 100 96.0 (90.1–98.9) 100 305.8 (242.5–385.6)
Day 182 100 76.0 (66.4–84.0) 100 114.4 (89.3–146.5)
20240 y Pre-vaccination 50 – 50 8.7 (6.6–11.4)
Day 21 50 78.0 (64.0–88.5) 50 146.6 (90.1–238.6)
Day 42 50 96.0 (86.3–99.5) 50 336.6 (247.8–457.1)
Day 182 50 84.0 (70.9–92.8) 50 133.5 (97.3–183.1)
41264 y Pre-vaccination 50 – 50 8.4 (6.6–10.7)
Day 21 50 70.0 (55.4–82.1) 50 127.8 (77.1–211.9)
Day 42 50 96.0 (86.3–99.5) 50 277.7 (194.3–397.0)
Day 182 50 68.0 (53.3–80.5) 50 98.0 (66.6–144.3)
N, number of subjects with available results; CI, confidence interval; ATP, according to protocol.
Figure1. Reverse cumulative curves for neutralising antibody responses 21 d after each of the two vaccine doses (Days 21 and 42) and six months after
the first vaccine dose (Day 182) (ATP cohort for immunogenicity). ATP, according to protocol.
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Discussion
This is the first study assessing the persistence of immunological
response against the A/California/07/2009 strain in Asian adults,
six months after vaccination with the AS03-adjuvanted H1N1
2009 pandemic influenza vaccine.
Persistence of HI immune response against the A/California/
07/2009 strain was observed for six months after the first vaccine
dose (SPR: 95%; SCR: 93%); the CHMP and CBER guidance
criteria for pandemic influenza vaccines were met and exceeded
at Day 182. The observations from this study is in agreement
with available data from studies in other adult populations that
reported that the immune response induced by two doses of the
3.75 mg HA AS03-adjuvanted H1N1 2009 vaccine persists for six
months after vaccination.
17,18 These observations are important
for assessment of disease management strategies in the context
of the WHO recommendations for the post-pandemic period
which stresses on continuous vigilance, surveillance and disease
management of circulating influenza strains.
19
A previous head-to-head comparison study in UK between a
similar AS03-adjuvanted H1N1 2009 vaccine and a non-
adjuvanted whole-virion H1N1 2009 vaccine in adults (including
those aged $ 65 y) reported that a single dose of the adjuvanted
vaccine was sufficient to induce immune responses meeting the
US and European regulatory criteria while two doses of the whole-
virion vaccine were required. In addition, a large proportion of the
participants were found to have protective levels of antibodies
against the vaccine strain even six months after vaccination with
two doses (although age-related decline was evident), indicating
that pandemic influenza vaccines can potentially confer immunity
against successive waves of the same virus.
20 This is in agreement
with previous studies using the AS03-adjuvanted H1N1 2009
vaccine that have demonstrated substantial benefits in terms of
induction of rapid, strong and long-lasting immune responses.
Theoretically, neutralization assays can capture a broad range of
anti-influenza antibody activities and are able to interrupt several
steps of the infectious life cycle of the virus. In contrast, HI assays
are largely restricted to measuring the receptor-binding blocking
activity of antibodies.
21 However, many different neutralising
assays with different variations in protocols and expression of
endpoints have been described
22 and it is likely that the biological
activity of antibodies measured by these different assays is variable.
The assay used in this study is characterized by a short incubation
time between the virus and the tested serum. Although the extent
of method-specific variation in neutralisation titer and its clinical
significance is unknown, assay validation demonstrated good assay
specificity (97% with 95% CI: 91.48–99.38%) and a good
correlation with the HI assay (r = 0.64) (unpublished GSK data).
The study demonstrated strong neutralising antibody response as
evident from the high VRRs following each of the two vaccine
doses and persistence of high VRRs for six months after the first
vaccine dose. Neutralizing antibody responses observed in the
study population confirmed the robust immunogenicity of the
vaccine and persistence of anti-A/California/07/2009-like anti-
bodies. Overall, the vaccine had a clinically acceptable safety
profile in the study population.
The epidemiology and characteristics of the H1N1 2009 virus
in Japan has been similar to that observed in other countries in the
northern hemisphere and the trends in incidence mirrored those
observed worldwide. Although there were fewer laboratory-
confirmed H1N1 2009 cases after February–March 2010, and
the last reported death due to H1N1 2009 in the pandemic
period was in July 2010,
3 the virus continued to circulate in the
post-pandemic phase, making it essential to investigate whether
pandemic vaccination programs led to long-term persistence of
immune response against the H1N1 2009 virus.
The present study advances information on the safety,
immunogenicity and long-term immunological persistence of this
AS03-adjuvanted H1N1 2009 pandemic influenza vaccine in
an Asian population. Contrary to the observations made by
Nicholson et al. using a similar vaccine in adults including the
elderly,
20 no age-related declined immunological response was
observed at Day 42 in the present study, and the data indicated
that the immunological response was persistent up to Month 6 in
both age strata (20–40 and 41–64 y). The safety profile of the
vaccine in Asian adults was comparable to previous reports and
no-Asia-specific safety concerns were reported. Thus, the data
obtained from this study provides a holistic worldwide dimension
to the safety and immunogenicity profile of the study vaccine
observed across different populations, now including this Japanese
population.
In conclusion, this study presents novel data on persistence of
immunological response against the H1N1 2009 virus in adults
and on neutralising antibody response induced by this H1N1
2009 pandemic influenza vaccine. It was established that
following two doses of a 3.75 mg HA AS03-adjuvanted H1N1
2009 pandemic influenza vaccine in adults aged 20–64 y,
immune response against the vaccine homologous A/California/
07/2009 strain persisted for at least six months after the first
vaccine dose. The immunological response met the US and
Table3. Percentage of subjects aged 20264 y with neutralizing antibodies titers $ 1:8, $ 1:16, $ 1:32 and $ 1:64 against the A/Netherlands/602/09 strain
[antigenically homologous to the vaccine strain] at all time points (ATP cohort for immunogenicity)
Time point $ 1:8 $ 1:16 $ 1:32 $ 1:64
N % (95% CI)
Pre-vaccination 100 51.0 (40.8261.1) 20.0 (12.7229.2) 12.0 (6.4220.0) 6.0 (2.2212.6)
Day 21 100 96.0 (90.1298.9) 85.0 (76.5291.4) 79.0 (69.7286.5) 65.0 (54.8274.3)
Day 42 100 100 (96.42100) 100 (96.42100) 98.0 (93.0299.8) 90.0 (82.4295.1)
Day 182 100 99.0 (94.62100) 96.0 (90.1298.9) 84.0 (75.3290.6) 68.0 (57.9277.0)
N, number of subjects with available results; CI, confidence interval; ATP: according to protocol
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European guidance criteria for pandemic influenza vaccines up to
six months after the first vaccine dose. These results will be
beneficial in evaluating the importance and effect of vaccination
with this AS03-adjuvanted pandemic influenza vaccine.
Materials and Methods
Study design and subjects. In the primary phase, 100 healthy
Japanese adults aged 20–64 y without history of clinically-
confirmed influenza infection or previous vaccination with a
novel H1N1 2009 vaccine or any seasonal influenza vaccination
within 14 d prior to study start were enrolled to receive 21 d
apart, two doses of a monovalent AS03-adjuvanted 3.75 mgH A
A/California/07/2009 pandemic influenza vaccine. The subjects
were further stratified by age (stratification ratio: 1:1) into 20–
40 y and 41–64 y age strata.
Written informed consent was obtained from all subjects prior to
conducting any study-related procedures. The study was conducted
in accordance with the Good Clinical Practice guidelines, the
Declaration of Helsinki and local regulations. All study-related
documents were approved by Institutional Review Boards.
Study vaccine. The H1N1 2009 pandemic influenza vaccine
was a monovalent, inactivated, split-virion antigen adjuvanted
with AS03A (Arepanrix
TM, a trademark of the GlaxoSmithKline
group of companies). The H1N1 viral seed for the vaccine was
prepared from the reassortant virus NYMC X-179A (New York
Medical College, New York) generated from the A/California/07/
2009 strain, as recommended by the WHO.
23 AS03A is an oil-in-
water emulsion-based Adjuvant System containing a-tocopherol
(11.86mg tocopherol).
Both vaccine doses were administered intramuscularly at
alternate deltoid muscles sides.
Immunogenicity assessments. Blood samples were collected
before vaccination, 21 d after each of the two vaccine doses and
six months after the first vaccine dose.
Serum samples collected six months after the first vaccine dose
(Day 182) were tested at GSK Biologicals Central Laboratory
using a validated in-house HI assay [cut-off: $ 1:10] that used
chicken erythrocytes as previously described.
24
The viral microneutralisation assay was performed on serum
samples collected at all time points at Viroclinics Biosciences
(Rotterdam, The Netherlands).
25 The sera were subjected to heat
treatment at 56°C for 30 min and then tested in triplicate.
The assay used a constant amount of A/Netherlands/602/2009
pandemic H1N1 Influenza virus (A A/California/07/2009-like
virus) mixed with serial 2-fold dilutions of serum samples. The
mixture of virus and serum was added to Madin-Darby Canine
Kidney (MDCK) cell cultures (10
4 cells per well) and incubated
for one hour at 37°C, following which the virus-antibody mixture
was removed from the wells by aspiration, cells were fed with fresh
culture medium and further incubated for 6 d at 37°C. After the
incubation period, the well supernatants were transferred into 96
well plates and a suspension of turkey red blood cells (RBCs) was
added to it; following an incubation for 60 min at 4°C, the culture
supernatants (virus replication) were visualized by haemagglutina-
tion of RBCs. The 50% neutralisation titer of a serum was
calculated by the Reed and Muench method.
26 The assay cut-off
was 1:8.
The evaluation of outcome measures of immune response was
based on the immunogenicity criteria for pandemic influenza
vaccines in adults as required by the CHMP: point estimates for
HI antibody SCR: . 40%, SPR: . 70% and GMFR: . 2.5 and
CBER: lower bound of 95% CI for HI antibody for SCR: $ 40%
and SPR: $ 70%.
27,28 SPR was defined as percentage of subjects
with a post-vaccination titer $ 1:40, SCR as percentage of
subjects with pre-vaccination titer , 1:10 and post-vaccination
titer $ 1:40 or pre-vaccination titer . 1:10 and at least 4-fold
increase in post-vaccination titer and GMFR as post-vaccination
fold increase in GMTs for HI antibodies. For neutralising
antibodies, immunological assessments were based on the VRRs
defined as percentage of subjects with either a pre-vaccination titer
, 1:8 and a post-vaccination titer $ 1:32, or a pre-vaccination
titer $ 1:8 and at least a 4-fold increase in post-vaccination titer.
Safety and reactogenicity assessments. Unsolicited adverse
events were recorded up to 84 d following the first vaccine dose;
pIMD (which are a subset of adverse events that include both
autoimmune diseases and other inflammatory and/or neurologic
disorders which may or may not have an autoimmune etiology),
AESI and SAEs occurring during the entire study period were
recorded.
Statistical analyses. The analyses of immunogenicity in terms
of HI antibodies at Day 182 were performed on the per-protocol
cohort for persistence, analyses of immunogenicity in terms of
neutralising antibodies at all time points were performed on the
per-protocol cohort for immunogenicity and the analyses of safety
were performed on the total vaccinated cohort (TVC). The
according to protocol cohort for immunogenicity included all
subjects who received both vaccine doses and met all protocol-
defined eligibility criteria and procedures and for whom data was
available at Days 21 and 42. The according to protocol cohort for
persistence included all subjects who received both vaccine doses
and met all protocol-defined eligibility criteria and procedures
and for whom data was available at Days 21, 42 and 182. The
TVC included all vaccinated subjects for whom data was available.
For the purpose of GMT calculations, antibody titers below the
cut-off value of each assay were substituted by half of the cut-off
value.
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